Navigation Links
Intrinsic Enrolls First Patient in Barricaid® Trial
Date:2/17/2011

WOBURN, Mass., Feb. 17, 2011 /PRNewswire/ -- Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid® device. Barricaid is designed to prevent reherniations following lumbar discectomy, while allowing the surgeon to retain as much of the native nucleus as possible preserving normal disc height and biomechanics. Barricaid accomplishes this by providing the added security of a bone-anchored device that can be used to close larger anular defects or in cases where anular integrity is in question.

The procedure was performed by Guido Dua, M.D., Chief of Neurosurgery, Middelheim Hospital in Antwerp, Belgium. Robert Hes, MD, Principal Investigator at Middelheim, stated, "What I like about the Barricaid device is that it provides an elegant solution to possible reherniation. Barricaid allows for a limited discectomy while offering the potential for secure closure of the anular defect and a reduction in both the risk of recurrent disc herniation and disc height loss.  I was very satisfied with the simplicity and ease of the procedure. I anticipate that we will be able to recreate the outstanding results seen in prior Barricaid studies."

"We are pleased to have begun our randomized study in Europe," said Noel Rolon, Intrinsic Vice President, Regulatory and Clinical Affairs. "The fact that we have started enrolling patients so quickly indicates the level of enthusiasm among our investigators.  It is clear that the positive clinical and commercial results recently presented at the DWG meeting in Bremen and published in the November 2010 issue of the European Spine Journal, provide a strong foundation for this post-marketing study."

Intrinsic is enrolling up to 800 patients in a prospective, randomized, superiority study comparing Barricaid to traditional limited discectomy. "We are exc
'/>"/>

SOURCE Intrinsic Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction
2. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
3. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
4. Cardiogenesis Enrolls First Two Patients in Its Feasibility Study of the PHOENIX® Combination Delivery System
5. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
6. BHR Pharma Enrolls First Patient in Phase 3 SyNAPSe Traumatic Brain Injury Trial
7. Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
8. Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
9. PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
10. Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
11. Facet Solutions Enrolls 100th Patient in US Pivotal IDE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 ... the addition of the  "Global Operating Room ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,An ... sterile environment in a healthcare facility used ... with technically advanced equipment, which ensures patient ...
(Date:8/22/2014)...  As the Medical Affairs, role has become more ... area are exploring methods to develop strong capabilities to ... at Best Practices, LLC is designed to give Medical ... key challenges they face. The consortium will provide a ... roundtable discussions where leaders discuss key findings from the ...
(Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
Breaking Medicine Technology:Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Best Practices' Medical Affairs Consortium Survey Has Achieved Strong Participation 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... 2011 Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... conference call and a live Internet webcast along with a ... ET (7:00 a.m. PT) to discuss results for the 2010 ... to participate on this call is (877) 295-5743, confirmation code ...
... MYL ) today announced that its subsidiary ... and 200 mg, under a previously announced settlement and ... company to have filed a substantially complete ANDA containing ... awarded 180 days of marketing exclusivity.   ...
Cached Medicine Technology:Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 2
(Date:8/22/2014)... 2014 Recently, iFitDress.com, a well-known wedding ... of discounted wedding gowns . In addition to ... these new products are provided with low shipping fees. ... to unveil the new wedding gowns. In our online ... for ladies to choose from. What’s more, all of ...
(Date:8/22/2014)... New Orleans, LA The LSU Health New ... Advanced Education Nursing Traineeship grant to increase access ... disadvantaged, underserved and under-represented groups, as well as ... the US Department of Health and Human Services ... will serve as the grant,s project director., The ...
(Date:8/22/2014)... 22, 2014 Natural Clear Vision , ... restore his own vision from legally blind to perfect 20/20 ... investigative review. , “There is a huge portion of ... everyday function, and most people just think that’s the way ... surgery that can be pretty risky at times,” reports Michaels. ...
(Date:8/22/2014)... time an oncogenic somatic mutation at amino acid 918 ... identified in small cell lung cancer (SCLC) tumors and ... produced increased intracellular signaling and cell growth. , SCLC ... 15% of all lung cancers and is strongly associated ... has been extensively examined for genomic alterations and targeted ...
(Date:8/22/2014)... Restore My Vision Today , ... Pearson to help people discover how they can get ... by instead improving their eyesight naturally has caught the ... , “There’s a reason why the glasses and contacts ... because people just assume that it’s their only option ...
Breaking Medicine News(10 mins):Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2
... disease could be more common than thought, experts say, , ... from rabies of a 17-year-old Texas girl -- diagnosed months ... their heads and wondering if such cases might be less ... possibility that abortive rabies can occur in humans and might ...
... ... enterprise platform for its revolutionary Evercore® – Enterprise Clinical Suite software system, now available ... ... Healthcare Technology , a leading medical informatics company, has launched a new enterprise platform ...
... ... ... ... ...
... , ... ... ... ...
... screening tool for early detection of prostate cancer (PCa) in ... PCa. The risk of suicide is increased among cancer patients ... among men diagnosed with PCa subsequent to PSA testing, a ... published in the March issue of European Urology , ...
... Two Spanish psychologists and a German neurologist have recently shown ... new noun is different from the part used when a ... taken using functional magnetic resonance, according to an article they ... "Learning nouns activates the left fusiform gyrus, while learning ...
Cached Medicine News:Health News:Texas Girl Recovers From Rabies Without Intensive Care 2Health News:TeraMedica Launches Evercore – Clinical Enterprise Suite 5.0 Now on Linux 2Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 2Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 3Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 4Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 5Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 6Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 7Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 8Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 9Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 10Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 11Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 12Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 13Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 14Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 15Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 16Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 17Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 18Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 19Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 20Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 21Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 22Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 23Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 24Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 25Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 26Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 27Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 28Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 29Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 30Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 31Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 32Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 33Health News:MedTrust Online Brings MICROMEDEX(R) DRUGDEX(R) From Thomson Reuters to Over 7,000 Online Oncologists 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: